Uncategorized

Lilly expects orforglipron obesity results in third quarter – Reuters

Posted on Author Tim Hodges Comments Off on Lilly expects orforglipron obesity results in third quarter – Reuters
  1. Lilly expects orforglipron obesity results in third quarter  Reuters
  2. Lilly’s Experimental Obesity Pill Holds Up to Scrutiny in Trial  Bloomberg.com
  3. Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine  Yahoo Finance
  4. Eli Lilly’s phase 1 amylin data impress analysts, pairing 11% weight loss with tolerable profile  Fierce Biotech
  5. Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s  wired.com